National Resilience Snares Takeda Plasma Development and Manufacturing Deal

Manufacturing newcomer National Resilience, already working on Moderna’s COVID-19 vaccine in Canada, has enlisted another high-profile client.

Resilience has clinched a deal to chip in on development and manufacturing of “multiple” products in Takeda’s plasma-derived therapies portfolio, the company said Tuesday. It plans to tackle the project from its 136,000-square-foot biomanufacturing plant in Mississauga, Ontario. 

In April 2021, the company acquired biologic drug substance maker Ology Bioservices, a UF startup and graduate of UF Innovate | Accelerate at Sid Martin Biotech. That deal bolstered Resilience’s biopharma production network with the addition of 300 new employees and 200,000-square-feet of workspace.

Read more about National Resilience Snares Takeda Plasma Development and Manufacturing Deal.